Chinese Journal of Pharmacovigilance ›› 2017, Vol. 14 ›› Issue (1): 36-39.
• Orignal Article • Previous Articles Next Articles
LIU Xiao, DENG Yi*
Received:
2017-02-16
Revised:
2017-02-16
Online:
2017-01-20
Published:
2017-02-16
Contact:
邓毅,男,本科,副主任医师,脑血管病与帕金森病临床诊疗。E-mail:liuxiaodalian@126.com
CLC Number:
LIU Xiao, DENG Yi. Prevention and Treatment Progress of Levodopa-induced Motor Fluctuations[J]. Chinese Journal of Pharmacovigilance, 2017, 14(1): 36-39.
[1] Connolly B S, Lang A E. Pharmacological treatment of Parkinson disease: a review [J]. JAMA, 2014, 311(16):1670-1683. [2] Ferreira J J, Katzenschlager R, Bloem B R, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease [J]. Eur J Neurol, 2013, 1(20):5-15. [3] Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench- to-bedside gap [J]. Lancet Neurol, 2010, 9(11):1106-1107. [4] Aquino C C, Fox S H. Clinical spectrum of levodopa-induced complications[J]. Mov Disord, 2015, 30(1):80-89. [5] Olanow C W, Watts R L, Koller W C. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines [J]. Neurology, 2001, 56(11 Suppl 5):1-88. [6] Quinn N. Fortnightly Review: Drug treatment of Parkinson’s disease[J]. Bmj Clinical Research, 1995, 310(6979):575-579. [7] Aquino C C, Fox S H. Clinical Spectrum of Levodopa-Induced Complications [J].Movement Disorders, 2015, 30(1), 80-89. [8] Muenter M D, Tyce G M. L-dopa therapy of Parkinson’s disease: plasma L-dopa concentration, therapeutic response, and side effects [J]. Mayo Clin Proc, 1971, 46(4):231-239. [9] Shoulson I, Glaubiger G A, Chase T N. On-off response: clinicaland biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients [J]. Neurology, 1975, 25(12): 1144-1148. [10] Fahn S. Fluctuations of disability in Parkinson’s disease:pathophysiological aspects. In: Marsden CD, Fahn S, eds. Movement Disorders [M]. London: Butterworth-Heinemann, 1981:123-145. [11] Merello M, Lees A J. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson’s disease [J]. J Neurol Neurosurg Psychiatry, 1992,55(11): 1024-1026. [12] Nutt J G, Gancher S T, Woodward W R. Does an inhibitory action of levodopa contribute to motor fluctuations? [J]. Neurology, 1988, 38(10):1553-1557. [13] Ahlskog J E, Muenter M D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J]. Mov Disord, 2001, 16(3):448-458. [14] Van Gerpen J A, Kumar N, Bower J H, et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990[J]. Arch Neurol, 2006, 63(2):205-209. [15] Kumar N, Van Gerpen J A, Bower J H, et al. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset [J]. Mov Disord, 2005,20(3):342-344. [16] Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease [J]. Mov Disord, 2013, 28(8):1064-1071. [17] Olanow C W, Stern M B, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009) [J]. Neurology, 2009, 72(21 Suppl 4):1-136. [18] Fahn S, Bressman S B. Should levodopa therapy for Parkinsonism be started early or late? Evidence against early treatment [J]. Can J Neurol Sci, 1984, 11(1 suppl):200-205. [19] Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease [J]. Arch Neurol, 1986, 43(4):402-405. [20] Nyholm D, Stepien V. Levodopa fractionation in Parkinson’s disease [J].J Parkinsons Dis, 2014, 4(1):89-96. [21] Hauser R A, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations:a phase 3 randomised, double-blind trial [J]. Lancet Neurol, 2013,12(4):346-356. [22] Stocchi F, Hsu A, Khanna S, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients [J]. Parkinsonism Relat Disord, 2014, 20(12):1335-1340. [23] Pahwa R, Stacy M A, Factor S A, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease [J].Neurology, 2007, 68(14):1108-1115. [24] LeWitt P A, Lyons K E, Pahwa R, et al. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study [J].Neurology, 2007, 68(16):1262-1267. [25] Schapira A H, Barone P, Hauser R A, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial [J]. Neurology, 2011, 77(8):767-774. [26] LeWitt P A, Ward C D, Larsen T A, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism [J]. Neurology, 1983,33(8):1009-1014. [27] Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group [J]. Neurology, 1997, 49(4):1060-1065. [28] Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson’s disease: a multicenter, crossover,controlled study [J]. Mov Disord, 1994, 9(4):431-436. [29] Korczyn A D, Brooks D J, Brunt E R, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study[J]. Mov Disord, 1998,13(1):46-51. [30] Clarke C E, Deane K D. Cabergoline versus bromocriptine for levodopa -induced complications in Parkinson’s disease [J]. Cochrane Database Syst Rev, 2001, (1):CD001519. [31] Poewe W H, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial [J]. Lancet Neurol,2007, 6(6):513-520. [32] Pahwa R, Factor S A, Lyons K E, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence -based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [J]. Neurology, 2006, 66(7): 983-995. [33] Rascol O, Brooks D J, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial [J]. Lancet, 2005, 365(9463):947-954. [34] Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study [J]. Arch Neurol, 2005, 62 (2):241-248. [35] Olanow C W, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double -dummy study [J]. Lancet Neurol, 2014, 13(2):141-149. [36] Fox S H. Non-dopaminergic treatments for motor control in Parkinson’s disease [J]. Drugs, 2013, 73(13):1405-1415. [37] Murata M, Hasegawa K, Kanazawa I, et al. Japan Zonisamide on PD Study Group. “Zonisamide improves wearing-off in Parkinson’s disease: A randomized, double-blind study”[J]. Mov Disord, 2015, 30(10):1343-1350. [38] Pourcher E, Huot P. Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson’s Disease [J]. Mov Disord Clin Practice, 2015, 2(4): 331-340. [39] Metman L V, Slavin K V. Advances in functional neurosurgery for Parkinson’s disease.[J]. Movement Disorders, 2015, 30(11):1461-1470. [40] Suchowersky O, Gronseth G, Perlmutter J, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [J]. Neurology, 2006, 66(7):976-982. [41] Tomlinson C L, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease [J]. Cochrane Database of Systematic Reviews, 2012, 11(7):CD002817. [42] Virmani T, Tazan S, Mazzoni P, et al. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease[J]. J Clin Mov Disord, 2016, 26(3):8. |
[1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
[2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
[3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
[4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
[6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
[7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
[8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
[9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
[10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
[11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
[12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
[13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
[14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
[15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||